Pancreatic Cancer Research

ResearcherBoehringer Ingelheim (United States)Active in the last 2 years

Robert J. Norgard

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-4245-6770; OpenAlex author ID A5008121919; NIH RePORTER profile ID 14809639. Sources: OpenAlex.

Their work

Papers
9 (first author 2, last author 0)
Trials
0
Grants
1
Labs led
0
Collaborators
43
Papers, trials and grants by year

2019: 1 paper · 2020: 2 papers, 1 grant · 2021: 2 papers · 2022: 2 papers · 2023: none · 2024: 1 paper · 2025: 1 paper

Papers 9

  1. Pancreatic cancer cachexia is mediated by PTHrP-driven disruption of adipose de novo lipogenesis Co-author DOI 10.1101/2025.06.03.657464↗
  2. Reshaping the Tumor Microenvironment of KRASG12D Pancreatic Ductal Adenocarcinoma with Combined SOS1 and MEK Inhibition for Improved Immunotherapy Response. Co-author DOI 10.1158/2767-9764.crc-24-0172↗
  3. Bcl-xL Enforces a Slow-Cycling State Necessary for Survival in the Nutrient-Deprived Microenvironment of Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-22-0431↗
  4. MYC Levels Regulate Metastatic Heterogeneity in Pancreatic Adenocarcinoma. First author DOI 10.1158/2159-8290.cd-20-1826↗
  5. Epigenetic and Transcriptional Control of the Epidermal Growth Factor Receptor Regulates the Tumor Immune Microenvironment in Pancreatic Cancer. Co-author DOI 10.1158/2159-8290.cd-20-0519↗
  6. PTHrP Drives Pancreatic Cancer Growth and Metastasis and Reveals a New Therapeutic Vulnerability. First author DOI 10.1158/2159-8290.cd-20-1098↗
  7. Pharmacologic Activation of the G Protein-Coupled Estrogen Receptor Inhibits Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1016/j.jcmgh.2020.04.016↗
  8. Tumor Cell-Intrinsic USP22 Suppresses Antitumor Immunity in Pancreatic Cancer. Co-author DOI 10.1158/2326-6066.cir-19-0661↗
  9. A biomimetic pancreatic cancer on-chip reveals endothelial ablation via ALK7 signaling. Co-author DOI 10.1126/sciadv.aav6789↗

Grants 1

  1. Calcium-signaling induced epithelial-mesenchymal plasticity in pancreatic cancer F31CA236269↗

Closest collaborators

The 25 strongest of 43 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Ben Z. Stanger · 7 shared papers, 2019–2022 · strength 0.78
  2. Jinyang Li · 6 shared papers, 2020–2022 · strength 0.68
  3. Jason Robert Pitarresi · 4 shared papers, 2020–2025 · strength 0.50
  4. Salina Yuan · 3 shared papers, 2020–2022 · strength 0.36
  5. Yogev Sela · 2 shared papers, 2021–2022 · strength 0.24
  6. Faiyaz Notta · 2 shared papers, 2021–2022 · strength 0.20
  7. Marcus A. Ruscetti · 1 shared paper, 2025 · strength 0.18
  8. Jessica Peura · 1 shared paper, 2025 · strength 0.18
  9. Nikita Bhalerao · 1 shared paper, 2025 · strength 0.18
  10. Michael Anthony Hollingsworth · 1 shared paper, 2025 · strength 0.18
  11. Paul M. Grandgenett · 1 shared paper, 2025 · strength 0.18
  12. Abhishek S. Kashyap · 1 shared paper, 2024 · strength 0.16
  13. Colin S. Sheehan · 1 shared paper, 2022 · strength 0.13
  14. Ian A. Blair · 1 shared paper, 2022 · strength 0.13
  15. Alexander Muir · 1 shared paper, 2022 · strength 0.13
  16. Maimon E. Hubbi · 1 shared paper, 2022 · strength 0.13
  17. Chi Van Dang · 1 shared paper, 2022 · strength 0.13
  18. Yanqing Jiang · 1 shared paper, 2021 · strength 0.11
  19. Robert H. Vonderheide · 1 shared paper, 2021 · strength 0.11
  20. Todd W. Ridky · 1 shared paper, 2020 · strength 0.11
  21. Christopher A. Natale · 1 shared paper, 2020 · strength 0.11
  22. David Balli · 1 shared paper, 2022 · strength 0.10
  23. John Christopher McAuliffe · 1 shared paper, 2022 · strength 0.10
  24. Pichai Raman · 1 shared paper, 2022 · strength 0.10
  25. Ravikanth Maddipati · 1 shared paper, 2022 · strength 0.10

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.